| Data-driven prediction of drug effects and interactions NP Tatonetti, PY Patrick, R Daneshjou, RB Altman Science translational medicine 4 (125), 125ra31-125ra31, 2012 | 453 | 2012 |
| Bioinformatics challenges for personalized medicine GH Fernald, E Capriotti, R Daneshjou, KJ Karczewski, RB Altman Bioinformatics 27 (13), 1741-1748, 2011 | 277 | 2011 |
| Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ... The Lancet 382 (9894), 790-796, 2013 | 222 | 2013 |
| Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans R Daneshjou, ER Gamazon, B Burkley, LH Cavallari, JA Johnson, ... Blood, The Journal of the American Society of Hematology 124 (14), 2298-2305, 2014 | 59 | 2014 |
| Pharmacogenomics KJ Karczewski, R Daneshjou, RB Altman PLoS Comput Biol 8 (12), e1002817, 2012 | 58 | 2012 |
| Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis J Couthouis, AR Raphael, R Daneshjou, AD Gitler PLoS Genet 10 (10), e1004704, 2014 | 44 | 2014 |
| Genotype-Guided Dosing of Vitamin K Antagonists (Dr. Maitland-Van Der Zee and colleagues reply) AH Maitland-van Der Zee, A De Boer, VG Manolopoulos New England Journal of Medicine 370 (18), 1765-1766, 2014 | 32 | 2014 |
| Pathway analysis of genome-wide data improves warfarin dose prediction R Daneshjou, NP Tatonetti, KJ Karczewski, H Sagreiya, S Bourgeois, ... BMC genomics 14 (S3), S11, 2013 | 26 | 2013 |
| PharmGKB summary: very important pharmacogene information for CYP4F2 ML Alvarellos, K Sangkuhl, R Daneshjou, M Whirl-Carrillo, RB Altman, ... Pharmacogenetics and genomics 25 (1), 41, 2015 | 24 | 2015 |
| Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges R Daneshjou, Y Wang, Y Bromberg, S Bovo, PL Martelli, G Babbi, ... Human mutation 38 (9), 1182-1192, 2017 | 20 | 2017 |
| PATH-SCAN: a reporting tool for identifying clinically actionable variants R Daneshjou, Z Zappala, KIM KUKURBA, SM Boyle, KE Ormond, ... Biocomputing 2014, 229-240, 2014 | 18 | 2014 |
| Pharmacogenomics and big genomic data: from lab to clinic and back again A Lavertu, G McInnes, R Daneshjou, M Whirl-Carrillo, TE Klein, ... Human molecular genetics 27 (R1), R72-R78, 2018 | 14 | 2018 |
| Genotype-guided dosing of vitamin K antagonists R Daneshjou, TE Klein, RB Altman The New England journal of medicine 370 (18), 1762, 2014 | 12 | 2014 |
| Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans A Gottlieb, R Daneshjou, M DeGorter, S Bourgeois, PJ Svensson, ... Genome medicine 9 (1), 1-9, 2017 | 7 | 2017 |
| Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans R Daneshjou, LH Cavallari, PE Weeke, KJ Karczewski, K Drozda, ... Molecular genetics & genomic medicine 4 (5), 513-520, 2016 | 5 | 2016 |
| Pernio-like eruption associated with COVID-19 in skin of color R Daneshjou, J Rana, M Dickman, JM Yost, A Chiou, J Ko JAAD Case Reports 6 (9), 892-897, 2020 | 3 | 2020 |
| Twitter Journal Clubs: Medical Education in the Era of Social Media R Daneshjou, AS Adamson JAMA dermatology, 2020 | 3 | 2020 |
| Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma KY Sarin, Y Lin, R Daneshjou, A Ziyatdinov, G Thorleifsson, A Rubin, ... Nature communications 11 (1), 1-8, 2020 | 3 | 2020 |
| Predicting venous thromboembolism risk from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges G McInnes, R Daneshjou, P Katsonis, O Lichtarge, R Srinivasan, S Rana, ... Human mutation 40 (9), 1314-1320, 2019 | 3 | 2019 |
| Pharmacogenomics in Dermatology: Tools for understanding gene-drug associations R Daneshjou, R Huddart, T Klein, R Altman Seminars in cutaneous medicine and surgery 38 (1), E19, 2019 | 1 | 2019 |
